Treatment Advances

February 11, 2025

Data from ASH 2024 shows olutasidenib’s impact on AML patients with mIDH1, achieving 35% remission. Learn more about this promising treatment.

February 02, 2025

FDA approves Treosulfan (Grafapex) for AML and MDS stem cell transplant conditioning, offering a new alternative to busulfan-based regimens.

January 16, 2025

Explore breakthroughs in pediatric AML, from cardiac care to therapies, highlighted at the ASH annual conference.

December 19, 2024

Learn about cellular therapies recommended for people who have TP53-mutant acute myeloid leukemia and myelodysplastic syndromes.

November 19, 2024

Learn about revumenib, a newly FDA-approved treatment for relapsed/refractory acute leukemias with the KMT2A gene translocation.

October 24, 2024

Discover key insights into AML donor selection, HLA mismatch, and the role of donor age in improving transplant outcomes and reducing complications.

October 22, 2024

Learn how venetoclax and decitabine helped a higher percentage of senior AML patients achieve a complete reduction in AML signs/symptoms and reach transplant.

October 04, 2024

What is the NPM1 mutation in acute myeloid leukemia (AML)? How common is it and how is it treated? Learn answers to these questions!

September 17, 2024

Learn why the FDA requested another trial for Iomab-B and what this means for AML patients seeking new treatment options.

September 06, 2024

Revumenib gains FDA Priority Review for treating relapsed KMT2A-rearranged leukemia, with a decision expected by September 26, 2024.